Daniel Patrick O’day Sells 15,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the sale, the chief executive officer directly owned 617,567 shares in the company, valued at $81,185,357.82. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Daniel Patrick O’day also recently made the following trade(s):

• On Tuesday, April 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $129.16, for a total transaction of $1,291,600.00.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $128.99 on Thursday. Gilead Sciences, Inc. has a one year low of $104.46 and a one year high of $157.29. The company’s 50-day moving average is $134.74 and its 200 day moving average is $134.31. The company has a market capitalization of $160.15 billion, a price-to-earnings ratio of 17.57 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the firm posted $1.81 EPS. Gilead Sciences’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio is 44.69%.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC raised its stake in Gilead Sciences by 144.2% during the 1st quarter. NewEdge Advisors LLC now owns 392,435 shares of the biopharmaceutical company’s stock worth $54,694,000 after acquiring an additional 231,715 shares during the period. First Nebraska Trust Co bought a new stake in Gilead Sciences during the 1st quarter worth approximately $530,000. Avidity Partners Management LP bought a new stake in Gilead Sciences during the 1st quarter worth approximately $2,787,000. Allen Capital Group LLC raised its stake in Gilead Sciences by 4.9% during the 1st quarter. Allen Capital Group LLC now owns 2,400 shares of the biopharmaceutical company’s stock worth $334,000 after acquiring an additional 112 shares during the period. Finally, Axiom Investment Management LLC bought a new stake in Gilead Sciences during the 1st quarter worth approximately $677,000. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of several recent research reports. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Scotiabank increased their price objective on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Mizuho increased their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Wolfe Research increased their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Finally, Argus increased their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead reported positive late-stage Livdelzi data in primary biliary cholangitis, reinforcing the drug’s commercial potential and supporting the company’s liver-disease growth story. Article Title
• Positive Sentiment: Additional coverage highlighted long-term efficacy and safety data for Livdelzi, which could help Gilead expand the drug’s reach in PBC. Article Title Article Title
• Positive Sentiment: Royal Bank of Canada upgraded Gilead from hold to moderate buy, a sign that analyst confidence is improving.
• Positive Sentiment: Cencora said it will support U.S. distribution of Kite’s FDA-approved CAR-T therapies, helping Gilead’s cell-therapy business maintain access and commercialization momentum. Article Title
• Neutral Sentiment: Gilead remains in the spotlight because investors are closely watching the stock and the company’s broader pipeline, but that attention alone does not change fundamentals. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan, which can still create a modest headwind for sentiment despite being routine. Article Title

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.